Chapter 3. Liberties and Constraints in the Development of Asymmetric Hydrogenations on a Technical Scale

  1. Dr. Hans-Ulrich Blaser2,
  2. Dr. Elke Schmidt3
  1. John F. McCarrity,
  2. Walter Brieden,
  3. Rudolf Fuchs,
  4. Hans-Peter Mettler,
  5. Beat Schmidt,
  6. Oleg Werbitzky

Published Online: 13 JAN 2004

DOI: 10.1002/3527602151.ch16

Asymmetric Catalysis on Industrial Scale: Challenges, Approaches and Solutions

Asymmetric Catalysis on Industrial Scale: Challenges, Approaches and Solutions

How to Cite

McCarrity, J. F., Brieden, W., Fuchs, R., Mettler, H.-P., Schmidt, B. and Werbitzky, O. (2004) Liberties and Constraints in the Development of Asymmetric Hydrogenations on a Technical Scale, in Asymmetric Catalysis on Industrial Scale: Challenges, Approaches and Solutions (eds H.-U. Blaser and E. Schmidt), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, FRG. doi: 10.1002/3527602151.ch16

Editor Information

  1. 2

    Solvias AG, P.O. Box, CH-4002 Basel, Switzerland

  2. 3

    Syngenta Crop Protection AG, CH-4058 Basel, Switzerland

Author Information

  1. Lonza AG, Process R & D, CH-3930 Visp, Switzerland

Publication History

  1. Published Online: 13 JAN 2004
  2. Published Print: 6 NOV 2003

ISBN Information

Print ISBN: 9783527306312

Online ISBN: 9783527602155

SEARCH

Keywords:

  • asymmetric hydrogenations;
  • technical scale;
  • Lonza biotin process;
  • screening;
  • josiphos;
  • Lonza dextrometorphan process;
  • imine hydrogenation;
  • scale-up;
  • 4-boc-piperazine-2(s)-n-tbutylcarboxamide;
  • SB-214857;
  • lotrafiban

Summary

This chapter contains sections titled:

  • Introduction

  • Asymmetric Hydrogenation in the Lonza Biotin Process

    • Historical Development

    • Laboratory Screening Experiments

      • Ligand Screening

      • Substrate Screening

      • Parameter Screening and Optimization

    • Scale-up and Production

    • Preparation of Josiphos (R)-(S)-PPF-P(tBu)2 on a Technical Scale

    • Conclusions

  • The Lonza Dextrometorphan Process

    • Introduction

    • Imine Hydrogenation

      • Background

      • Screening Experiments

      • Optimization Phase: Development of an Economic Process

    • Scale-up

    • Conclusion

  • 4-Boc-piperazine-2(S)-N-tbutylcarboxamide

    • Introduction

    • Initial Studies

    • Scale-up

    • Further Improvements in Synthetic Strategy

    • Conclusions

  • Intermediates for SB-214857 (Lotrafiban)

    • Introduction

    • Initial Screening of Catalysts

    • Statistically Evaluated Screening of Experimental Conditions